You cannot add another "Article: Updated results of the phase III COLUMBUS trial further solidify BRAF/MEK combinations as standard of care for BRAF-mutated advanced melanoma" to your cart. View cart

Article: Rebuttal to ‘The COMPARZ study presented at ESMO 2012: how pliable is non-inferiority?’

€3.03

SKU: product-article-11182 Category: General

Description
Reviews (0)

Description

Rebuttal to ‘The COMPARZ study presented at ESMO 2012: how pliable is non-inferiority?’

Reviews

There are no reviews yet.

Be the first to review “Article: Rebuttal to ‘The COMPARZ study presented at ESMO 2012: how pliable is non-inferiority?’”

You must be logged in to post a review.

Top

Article: Rebuttal to ‘The COMPARZ study presented at ESMO 2012: how pliable is non-inferiority?’

Description

Reviews

Related products

Article: Highlights in squamous cell carcinoma of the head and neck

Article: Highlights in breast cancer

Article: INTRODUCTION

Article: Highlights in genitourinary cancers